Table 2.
Clinical trials of vandetanib in patients with thyroid cancer
| Authors and references | Drug | Thyroid cancer | Responses
|
|||
|---|---|---|---|---|---|---|
| PR | SD | PD | PFS (months) | |||
| Wells et al88 | Vandetanib | 30 MTC | 20% | 53% | 3% | 27.9 |
| Robinson et al89 | Vandetanib | 19 MTC | 16% | 53% | 16% | 5.6 |
| Leboulleux et al91 | Vandetanib | 145 DeTC | 8% | 57% | 11.1 | |
| Wells et al92 | Vandetanib | 231 MTC | 45% | 42% | ||
| Chougnet et al95 | Vandetanib | 60 MTC | 20% | 55% | 12% | 16.1 |
Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; MTC, medullary thyroid cancer; DeTC, dedifferentiated thyroid cancer.